Topiramate for the treatment of alcohol dependence: Comparison with naltrexone

European Addiction Research

Volumn 17, Issue 1, 2010, Pages 29-36

  Flórez, Gerardo ^b   Saiz, Pilar A ^a   García Portilla, Paz ^a   Álvarez, Sandra ^b   Nogueiras, Luis ^b   Bobes, Julio ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Galician Health System   (Spain)

Author keywords

Alcohol dependence; Craving; Naltrexone; Topiramate; Treatment

Indexed keywords

ALCOHOL; CLORAZEPATE; DISULFIRAM; NALTREXONE; TOPIRAMATE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DRUG DOSE INCREASE; DRUG EFFICACY; EMPLOYMENT STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DRINKING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; WITHDRAWAL SYNDROME; WORLD HEALTH ORGANIZATION;

ALCOHOL DRINKING; ALCOHOLISM; EXCITATORY AMINO ACID AGENTS; FEMALE; FRUCTOSE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NALTREXONE; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77958135972     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320471     Document Type: Article

References (37)

1. World Health Organization: WHO global status report on alcohol 2004. Geneva, World Health Organization, 2004.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Publishing, 2000.
3. Grobin AC, Matthews DB, Devaud LL, Morrow AL: The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacol 1998; 139: 2-19.
4. Lovinger DM, White G, Weight FF: Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 1989; 243: 1721-1724.
5. Morrow DL, Devaud LL, Bucci D, Smith BD: GABAA and NMDA receptor subunit mRNA expression in ethanol dependent rats. Alcohol Alcohol 1994; 2: 89-95.
6. Koob GF, Le Moal M: Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52-58.
7. Johnson BA: Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005; 19: 873-896.
8. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ: Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361: 1677-1685.
9. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ: Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol: dependent individuals. Arch Gen Psychiatry 2004; 61: 905-912.
10. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait- Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM: Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641-1651.
11. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait- Daoud N, Addolorato G, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM: Improvement of physical health and quality of life of alcohol: dependent individuals with topiramate treatment. Arch Intern Med 2008; 168: 1188-1199.
12. World Health Organization: ICD-10, 10th Revision of the International Classification of Diseases. Madrid, World Health Organizaion, 1992.
13. Rehm J, Room R, Monteiro M, Gmel G, Graham K, Rehn N, Sempos CT, Jernigan D: Alcohol use; in Ezzat M, Lopez AD, Rodgers A, Murray CJL (eds): Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva, World Health Organization, 2004, vol 1, pp 995-1108.
14. Kokkevi A, Hartgers C: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1995; 1: 208-210.
15. Sobell LC, Sobell MB: Alcohol timeline followback user's manual. Toronto, Addiction Research Foundation, 1995.
16. Chang PH, Steinberg MB: Alcohol withdrawal. Med Clin North Am 2001; 85: 1191-1212.
17. Srisurapanot M, Jarusuraisin N: Naltrexone for the treatment of alcoholism: a meta- nalysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8: 267-280.
18. Volpicelli JR, Pettinati HM, McLellan AT, McLellan T, O'Brien CHP: Enhanced medication and treatment adherence for addiction treatment: the BRENDA model. New York, Guilford Press, 2001.
19. Anton RF, Moak DH, Latham P: The obsessive compulsive drinking scale: a self- ated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995; 19: 92-99.
20. Fagerström KO: Measuring degrees of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978; 3: 235-241.
21. Loranger AW, Sartorius N, Andreoli P, Berger P, Buchheim P, Channabasavanna SM, Coid B, Dahl A, Diekstra RF, Ferguson B: The international personality disorder examination. Arch Gen Psychiatry 1994; 51: 215-224.
22. Rollnick S, Heather N, Gold R, Hall W: Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict 1992; 87: 743-754.
23. Janca A, Kastrup M, Katschnig H, López- Ibor JJJr, Mezzich JE, Sartorius N: The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Soc Psychiatr Psychiatr Epidemiol 1996; 31: 349-354.
24. EuroQoL Group: EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
25. Allen JP, Litten RZ, Strid N, Sillanaukee P: The role of biomarkers in alcoholism medication trials. Alcoholism Clin Exp Res 2001; 25: 1119-1125.
26. Lingjaerd O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. Acta Psychiatr Scand 1987; 76: 1-100.
27. Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self- eported measure of medication adherence. Med Care 1986; 24: 67-74.
28. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A: COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017.
29. Babor TF, Longabaugh R, Zweben A, Fuller RK, Stout RL, Anton RF, Randall CL: Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. J Stud Alcohol 1994; 12: 101-111.
30. Cisler RA, Zweben A: Development of a composite measure for assessing alcohol treatment outcome: operationalization and validation. Alcoholism Clin Exp Res 1999; 23: 263-271.
31. Stout RL: Methodological and statistical considerations in measuring alcohol treatment effects. Alcoholism Clin Exl Res 2003; 27: 1686-1691.
32. Martinotti G, Di Nicola M, Romanelli R, Andreoli S, Pozzi G, Moroni N, Janiri L: High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol- dependent patients. Hum Psychopharmacol 2007; 22: 149-156.
33. Verheul R, Van Den Brink W, Geerlings P: A three-pathway psychological model of craving for alcohol. Alcohol Alcohol 1999; 34: 197-222.
34. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G: Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504-508.
35. Miranda R, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swif, R, Ray L, McGeary J: Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 2008; 32: 489-497.
36. Alapati A: Side effect profile on two different starting dose of topiramate. Epilepsia 1999; 40: 141-142.
37. Ait-Daoud N, Lynch WJ, Penberthy JK, Breland AB, Marzani-Nissen GR, Johnson BA: Treating smoking dependence in depressed alcoholics. Alcohol Res Health 2006; 29: 213-220.